Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 03/31/23
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/31/23
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 03/02/23
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 02/21/23
Checkpoint Therapeutics to Participate in the B. Riley Securities' 3rd Annual Oncology ConferenceGlobeNewsWire • 01/17/23
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 01/04/23
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 12/15/22
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/08/22
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/12/22
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell CarcinomaGlobeNewsWire • 06/16/22
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 06/06/22
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/19/22
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory AgencyGlobeNewsWire • 05/13/22
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/12/22
Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/28/22
Checkpoint Therapeutics: Potential Upside Based On Marketing Application SubmissionsSeeking Alpha • 04/18/22
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley SecuritiesGlobeNewsWire • 04/04/22
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/28/22